The Highest-Rated CEOs In America

These Are The Highest-Rated CEOs In America

Highest Rated CEOs

Mark Zuckerberg still ranks high, but there are a couple of surprises on this year's list. Here's what the best CEOs had in common.

The votes have been counted and analyzed and the winners of Glassdoor’s 2016 Highest Rated CEOs at large companies in the U.S. are in

Mark Zuckerberg claimed fourth place again while Salesforce CEO Marc Benioff made a big move, rising 15 spots to number six from number 21 last year. Google’s Larry Page cinched the number one spot last year, but the company’s new chief, Sunar Pichai, has already inspired employees’ favor coming in at number seven with a 96% approval rating.

The Top 10 Highest Rated CEOs

Bain & Company’s Bob Bechek (99% approval)
Ultimate Software’s Scott Scherr (99% approval)
McKinsey & Company’s Dominic Barton (99% approval)
Facebook’s Mark Zuckerberg (97% approval)
LinkedIn’s Jeff Weiner (97% approval)
Salesforce's Marc Benioff (97% approval)
Google's Sundar Pichai (96% approval)
Apple's Tim Cook (96%)
Nestle Purina Pet Care's Joseph R. Sivewright (96% approval)
Red Hat's Jim Whitehurst (96% approval)

Several leaders made the list for the first time including Nestle Purina PetCare’s Joseph Sivewright, debuting at number nine, NBCUniversal’s Stephen Burke at number 39, and lululemon’s Laurent Potdevin coming in at number 48.

Glassdoor’s ranking isn’t just a popularity contest. According to the researchers who conduct this analysis annually, the results were based on anonymous employees' feedback on the platform through a company review. These employees reported on whether they approve or disapprove of their CEO, as well as provide insight about their job, work environment, and employer over the past year.

In order to be included for consideration, a CEO’s company has to employ at least 1,000 people, have a minimum of 100 Glassdoor-approved company reviews, along with 100 or more CEO approval ratings, and at least 100 senior management ratings, from current and former U.S.-based employees. Reviews are accepted from full-time, part-time, contract, and freelance workers, but not interns.

Employee satisfaction is intimately tied to a company’s culture and values as well as trust in senior leadership, according to another study by Glassdoor. Another study by Edelman indicates that trust is hard-won. Among the other notable findings, trust decreases down an organization’s hierarchy as employees say they trust peers more than CEOs when it comes to company information.

In the case of Bain & Company, employees reported their faith in leadership this way: "Management works hard to make things sustainable" and "Strong leaders are willing to take the time to do the right thing and support developing employees."

Scott Scherr at Ultimate Software inspired similar sentiments. "Scott is the sweetest man alive and that’s why the company has such amazing culture… he takes care of anyone and everyone around him," wrote one employee in outside sales. Another wrote, "Scott started Ultimate 25 years ago and since he put people first way back then, the company today is full of empowered, helpful, and loving employees."

At Facebook, a site selection program manager wrote, "Mark Zuckerberg, Sheryl Sandberg, Chris Cox, and the rest of the leadership team, inspiring, smart and totally real."

Glassdoor career trends analyst Scott Dobroski notes that while this is not the first time female CEOs have made the list, 2016 is the year that has the most women represented. Dobroski points out that in 2013, Victoria's Secret CEO Sharen Turney made the list, and in 2014, both Turney and Yahoo's Marissa Mayer were in the Top 50. No women made the list in 2015, says Dobroski, but Glassdoor recognized the five highest-rated women CEOs, such as General Motor's Mary Barra, who didn’t rank in the Top 50, but were very highly rated by their employees.

Four female CEOs broke through the top 50 (There were none on the 2015 list)

#17 In-N-Out Burger’s Lynsi Snyder
#28 Staffmark’s Lesa Francis
#31 Enterprise Holdings’ Pamela Nicholson
#41 Deloitte’s Cathy Engelbert

Dobroski says that all of the top CEOs share common traits including strong leadership, dedication to company mission, commitment to professional growth opportunities, investment in company culture, and being personable and approachable. He points out that CEOs, like every other person, are unique individuals. "We do see themes that differ on how they lead a company and a workforce independent of what gender he or she is," he notes.

A recent study from DDI, a global HR consulting firm, revealed similar findings. The report indicated that both men and women score similarly in their ability to drive business.

For CEOs making the list for the first time, Dobroski says it is interesting to note that several are leading workforces that cross time zones and boundaries. "When we look at what their employees have to say, we see that they don't mention one-on-one or a lot of face time, " he explains, "but we see employees talking favorably that these CEOs have found a way to consistently communicate with all employees, including letting them know where the company stands, why their work matters and what's coming up next for the business."

At EY, one employee wrote: "Leadership and team members help build a team environment where everyone has a voice. Leadership recognizes individuals for their contributions and provides guidance."

Says Dobroski: "Employees like this in a leader because it reminds them that their work does impact business and lets them know what's on the horizon to motivate them."


source: fastcompany

U.S. sues Novartis over kickbacks, second case this week

The U.S. government on Friday announced its second civil fraud lawsuit against Novartis AG in four days, accusing a unit of the Swiss drugmaker of paying multimillion-dollar kickbacks to doctors in exchange for prescribing its drugs.

NOVARTIS

Authorities said the Basel-based company for a decade lavished healthy speaking fees and "opulent" meals, including a nearly $10,000 (6,459 pounds) dinner for three at the Japanese restaurant, Nobu, to induce doctors to prescribe its drugs. They said this led to the Medicare and Medicaid programs paying millions of dollars in reimbursements based on kickback-tainted claims for medication such as hypertension drugs Lotrel and Valturna and the diabetes drug Starlix. The charges are detailed in a whistleblower lawsuit first filed against Novartis Pharmaceuticals Corp by a former sales representative in January 2011 and which the U.S. government has now joined. Twenty-seven U.S. states, the District of Columbia and the cities of New York and Chicago are also plaintiffs in the lawsuit, which seeks triple damages under the federal False Claims Act. "Novartis corrupted the prescription drug dispensing process," U.S. Attorney Preet Bharara in Manhattan said in a statement. "For its investment, Novartis reaped dramatically increased profits on these drugs, and Medicare, Medicaid, and other federal healthcare programs were left holding the bag." On Tuesday, the government accused Novartis of inducing pharmacies to switch thousands of kidney transplant patients to its immunosuppressant drug Myfortic in exchange for kickbacks disguised as rebates and discounts. Novartis spokeswoman Julie Masow said the company disputes the claims in both lawsuits and will defend itself. She also said physician speaker programs are "an accepted and customary practice" in the industry. People who file whistleblower lawsuits, sometimes known as "qui tam" lawsuits, on behalf of the government under the False Claims Act share in recovered damages. The United States does not participate in all such lawsuits, but often joins cases it believes have greater merit. The original lawsuit against East Hanover, New Jersey-based Novartis Pharmaceuticals was filed by Oswald Bilotta, who now lives in North Carolina. He did not immediately respond to a request for comment. "We believe that Novartis' alleged payment of kickbacks is yet another example of abuse in the pharmaceutical industry that contributes to skyrocketing medical costs," James Miller, a partner at Shepherd, Finkelman, Miller, and Shah in Chester, Connecticut representing Bilotta, said in a statement. A $9,750 DINNER According to the complaint, from January 2002 to November 2011, Novartis often paid doctors to speak about its drugs and programs that were supposed to have educational purposes, but which in reality were often social occasions or not held at all. Authorities said that for Lotrel, Valturna and Starlix alone, the company spent nearly $65 million and conducted more than 38,000 speaker programs over the decade. The complaint describes a variety of alleged improper programs, including seven at Hooters restaurants that Novartis sales representatives attended, and pricey meals to which Novartis allegedly treated doctors. Among these meals were dinners at high-end Chicago restaurants such as Japonais and L20, a $2,016 dinner for three at Smith & Wollensky in Washington, D.C. and the $9,750 dinner for three at Nobu in Dallas in December 2005. Satow, the Novartis spokeswoman, said speaker programs are "promotional programs" designed to inform physicians how to use the company's medicines. Novartis "invests significant time and resources to help ensure these programs are conducted in an ethical and responsible manner," she said. "We are dedicated to doing it right. Bilotta filed his lawsuit four months after Novartis in September 2010 agreed to pay $422.5 million to resolve criminal and civil liability over its marketing of several drugs, including the epilepsy drug Trileptal. The case is U.S. ex rel. Bilotta v. Novartis Pharmaceuticals Corp, U.S. District Court, Southern District of New York, No. 11-00071.

source link: www.4-traders.com